Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
Weekly Digest – October 2025 Weekly Digest – October 2025 29 September 2025: Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase 3 trial in patients with high-risk early breast cancer […]
Weekly Digest – July 2025 Weekly Digest – July 2025 10 July 2025: PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results PDS […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics has dosed the first patient […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Corbus posts first US data on challenger to Pfizer’s ADC Padcev Corbus Pharmaceuticals’ western trial of its ADC showed a 27% response rate, aligning with prior Chinese […]
Weekly Digest – November 2024 Weekly Digest – November 2024 11 Nov 2024: Alphamab Oncology Unveils Promising Clinical Data on Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024 Alphamab Oncology presented first-in-human results of JSKN033, a subcutaneous co-formulation combining […]
Epilepsy digest American Academy of Neurology – 2021 Epilepsy digest American Academy of Neurology – 2021 UCB Pharma presentations @ AAN: Briviact and Nayzilam Briviact (brivaracetam) – UCB Pharma Safety and tolerability of intravenous brivaracetam in patients with epilepsy on […]
Epilepsy digestAmerican Academy of Neurology – 2021 Epilepsy digestAmerican Academy of Neurology – 2021 Neurelis presentations @ AAN: Valtoco Valtoco (Diazepam) – Neurelis Abstract title Trial details Efficacy Safety Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using […]
Epilepsy digestAmerican Academy of Neurology – 2021 Epilepsy digest American Academy of Neurology – 2021 SK BioPharmaceuticals @ AAN: XCOPRI XCOPRI (Cenobamate, ONTOZRY) – SK BioPharmaceuticals SK Pharmaceuticals presented multiple posters and oral sessions providing information on long-term safety and […]
